Literature DB >> 16542200

Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects.

D Singh1, R Tal-Singer, I Faiferman, S Lasenby, A Henderson, D Wessels, A Goosen, N Dallow, R Vessey, M Goldman.   

Abstract

AIMS: Spirometry, plethysmography and impulse oscillometry (IOS) measure different aspects of lung function. These methods have not been compared for their ability to assess long- and short-acting anticholinergic agents. We therefore performed a double-blind, placebo-controlled, four-way cross-over study in 30 healthy subjects.
METHODS: Single doses of tiotropium bromide (Tio) 54 and 18 mcg, ipratropium bromide (IB) 40 mcg and placebo were administered. Specific conductance (sGaw), total lung capacity (TLC), inspiratory capacity (IC) and residual volume (RV) were measured using plethysmography, while IOS measured resistance (R5-25) and reactance (RF and X5). Pulmonary function was measured for 26 h post dose.
RESULTS: Tio caused significant improvements in sGaw, forced expiratory voume in 1 s (FEV(1)), maximum mid-expiratory flow (MMEF) and R5-R25 at time points up to 26 h, with no clear differences between doses. IB improved the same parameters, but only up to 8 h. The weighted mean change (0-24 h) caused by Tio 54 mcg compared with placebo for FEV(1) was 240 ml (95% confidence interval 180, 300), while for sGaw the ratio of geometric means (Tio compared with placebo) was 1.35 (1.28, 1.41). Neither drug caused consistent statistically significant changes in RF, forced vital capacity, TLC or IC over 26 h. RV was significantly improved from 8 to 24 h by Tio 54 mcg only.
CONCLUSIONS: In addition to spirometry, IOS resistance measurements and sGaw can distinguish between the effects of long- and shortacting anticholinergic effects in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542200      PMCID: PMC1885034          DOI: 10.1111/j.1365-2125.2006.02594.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  A comparison of lung function methods for assessing dose-response effects of salbutamol.

Authors:  Catherine M Houghton; Ashley A Woodcock; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Measuring bronchodilation in COPD clinical trials.

Authors:  Z L Borrill; C M Houghton; A A Woodcock; J Vestbo; D Singh
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 3.  Clinical applications of forced oscillation to assess peripheral airway function.

Authors:  Michael D Goldman; Constantine Saadeh; David Ross
Journal:  Respir Physiol Neurobiol       Date:  2005-08-25       Impact factor: 1.931

Review 4.  Tiotropium bromide.

Authors:  Nicholas J Gross
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

5.  Ba 679 BR, a novel long-acting anticholinergic bronchodilator.

Authors:  B Disse; R Reichl; G Speck; W Traunecker; K L Ludwig Rominger; R Hammer
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

6.  A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma.

Authors:  C M Houghton; A A Woodcock; D Singh
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 7.  The role of anticholinergics in chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Am J Med       Date:  2004-12-20       Impact factor: 4.965

8.  Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.

Authors:  F P Maesen; J J Smeets; T J Sledsens; F D Wald; P J Cornelissen
Journal:  Eur Respir J       Date:  1995-09       Impact factor: 16.671

9.  Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.

Authors:  Bartolome Celli; Richard ZuWallack; Susan Wang; Steven Kesten
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

10.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Authors:  D E O'Donnell; T Flüge; F Gerken; A Hamilton; K Webb; B Aguilaniu; B Make; H Magnussen
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

View more
  9 in total

1.  Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction.

Authors:  Sophie J Bradley; Coen H Wiegman; Max Maza Iglesias; Kok Choi Kong; Adrian J Butcher; Bianca Plouffe; Eugénie Goupil; Julie-Myrtille Bourgognon; Timothy Macedo-Hatch; Christian LeGouill; Kirsty Russell; Stéphane A Laporte; Gabriele M König; Evi Kostenis; Michel Bouvier; Kian Fan Chung; Yassine Amrani; Andrew B Tobin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-08       Impact factor: 11.205

2.  Application of impulse oscillometry and bronchial dilation test for analysis in patients with asthma and chronic obstructive pulmonary disease.

Authors:  Yueyue Li; Yang Chen; Ping Wang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD.

Authors:  Zoë L Borrill; Catherine M Houghton; Ruth Tal-Singer; S Rupert Vessey; Isidore Faiferman; Stephen J Langley; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

4.  Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.

Authors:  Anthony Cahn; Ruth Tal-Singer; Isabelle J Pouliquen; Rashmi Mehta; Andrew Preece; Kelly Hardes; Glenn Crater; Amanda Deans
Journal:  Clin Drug Investig       Date:  2013-07       Impact factor: 2.859

Review 5.  Oscillometry of the respiratory system: a translational opportunity not to be missed.

Authors:  Lennart K A Lundblad; Annette Robichaud
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-04-06       Impact factor: 5.464

6.  Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.

Authors:  Jutta Beier; Jan van Noord; Amanda Deans; Jean Brooks; Claire Maden; Suus Baggen; Rashmi Mehta; Anthony Cahn
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-03-05

7.  Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.

Authors:  Virginia Norris; Claire Ambery
Journal:  Drugs R D       Date:  2014-12

8.  Normal limits for oscillometric bronchodilator responses and relationships with clinical factors.

Authors:  Kanika Jetmalani; Nathan J Brown; Chantale Boustany; Brett G Toelle; Guy B Marks; Michael J Abramson; David P Johns; Alan L James; Michael Hunter; Arthur W Musk; Norbert Berend; Claude S Farah; David G Chapman; Cindy Thamrin; Gregory G King
Journal:  ERJ Open Res       Date:  2021-11-08

9.  Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers.

Authors:  Neil E Alexis; John C Lay; Angela Haczku; Henry Gong; William Linn; Milan J Hazucha; Brad Harris; Ruth Tal-Singer; David B Peden
Journal:  Environ Health Perspect       Date:  2008-06       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.